PML

Across TCGA pan-cancer cohorts, PML mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PML data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher PML mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PML expression acts as an unfavorable survival marker, although some lineages such as LUAD and HNSC show a favorable association.

COAD, LSCC, and PDAC are the cancer types where PML mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	II,III,IV	0.876	1.000	.015	72	view →
LSCC	DFS	Tertile	II,III,IV	0.490	0.918	<.001	28	view →
PDAC	DFS	Tertile	IV	0.203	0.752	.024	5	view →
LUAD	OS	Median	All	0.823	0.613	.037	2	view →
HNSC	DFS	Quartile	III,IV	1.000	0.896	.029	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PML–COAD (DFS)

Open the COAD breakdown →